Regenerative Medicine Market by Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy - Global Forecast to 2025 - ResearchAndMarkets.com

The "Regenerative Medicine Market - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Regenerative Medicine Market is Projected to Reach USD 17.9 Billion by 2025 from USD 8.5 Billion in 2020, at a CAGR of 15.9% during the Forecast Period.

Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

List of Companies Profiled in the Report:

• 3M (US)
• Allergan plc (Ireland)
• Amgen, Inc. (US)
• Aspect Biosystems (Canada)
• bluebird bio (US)
• Kite Pharma (US)
• Integra LifeSciences Holdings Corporation (US)
• MEDIPOST Co., Ltd. (South Korea)
• Medtronic plc (Ireland)
• Anterogen Co., Ltd. (South Korea)
• MiMedx Group (US)
• Misonix (US)
• Novartis AG (Switzerland)
• Organogenesis Inc. (US)
• Orthocell Limited (Australia)
• Corestem, Inc. (South Korea)
• Spark Therapeutics (US)
• APAC Biotech (India)
• Shenzhen Sibiono GeneTech Co., Ltd. (China)
• Smith & Nephew plc (UK)
• Stryker Corporation (US)
• Takeda Pharmaceutical Company Limited (Japan)
• Tego Science (South Korea)
• Vericel Corporation (US)
• Zimmer Biomet (US)

For more information about this report visit https://www.researchandmarkets.com/r/m8gpzw

View source version on businesswire.com: https://www.businesswire.com/news/home/20201127005310/en/